SCHEMBL30714671

SCHEMBL30714671

Cc1ncsc1COc1ccc2nn(C)c(C(=O)NCC(C)(C)CO)c2c1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IKBKE Q14164 1/20 0.34
AURKB Q96GD4 1/20 0.34
TBK1 Q9UHD2 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MCHR1 Q99705 7/20 0.33
EGLN2 Q96KS0 3/20 0.33
EGLN1 Q9GZT9 3/20 0.33
PDE10A Q9Y233 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TYK2 P29597 2/20 0.31
PDE4D Q08499 2/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
CNR2 P34972 1/20 0.31
CNR1 P21554 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714601 0.88 MCHR1 (0.36) KDM4EALDH1A1MCHR1EGLN2EGLN1
SCHEMBL30714559 0.88 CNR1 (0.36) KDM4EMCHR1EGLN2EGLN1NPC1
SCHEMBL30714654 0.84 MCHR1 (0.34) ALDH1A1MCHR1NPC1RAB9AMEN1
SCHEMBL30714703 0.84 ALDH1A1 (0.46) KDM4EALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL30714692 0.84 MCHR1 (0.34) MCHR1
SCHEMBL30714750 0.83 MCHR1 (0.34) KDM4EALDH1A1MCHR1EGLN2EGLN1
SCHEMBL31742254 0.83 MCHR1 (0.33) MCHR1PDE10A
SCHEMBL30714592 0.83 EGLN2 (0.45) KDM4EALDH1A1EGLN2EGLN1MEN1
SCHEMBL30714653 0.82 SCN9A (0.36) MCHR1
SCHEMBL30714636 0.82 MCHR1 (0.34) MCHR1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 IKBKE 1994/4885AURKB 3299/4885TBK1 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.